As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
(1) 5-substituted 2' -deoxyuridine analogues (e.g., Avodine)
(2) Nucleoside analogs (e.g. Entecavir)
(3) Pyrophosphate analogs (e.g., Sodium terephthalate)
(4) NRTI drugs (e.g. Lamivudine)
(5) NNRTIs (e.g., Nevirapine)
(6) Protease inhibitors (e.g., Gezoprevir)
(7) Integrase inhibitors (e.g., Dolutegravir)
(8) Entry inhibitors (e.g., Enfuvirtide)
(9) Acyclic guanosine analogs (such as Guanidine)
(10) Acyclic nucleoside ester analogs (such as Adefovir dipivoxil)
(11) HCV NS5A and NS5B inhibitors (e.g., Sofosbuvir).
(12) Influenza virus inhibitors (e.g., Peramivir)
(13) Interferons, immune stimulators, oligonucleotides, and anti-mitotic inhibitors